$RCKT insider trading
Over the last 12 months, Rocket Pharmaceuticals insiders reported 1 buy totaling $34K and 19 sales totaling $687K across SEC Form 4 filings.
- Bought · 12m
- $34K 1 event
- Sold · 12m
- $687K 19 events
- Events · 12m
- 20 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Wilson MartinGeneral Counsel · O | ▼ Sale | 631 | $3.38 | $2K | -0.1% | — |
| Aug 18, 2026 | Shah GauravCEO · O | ▼ Sale | 2,293 | $3.38 | $8K | -0.2% | — |
| Aug 13, 2026 | Shah GauravCEO · O | ▼ Sale | 2,837 | $3.38 | $10K | -0.3% | — |
| Aug 13, 2026 | Wilson MartinGeneral Counsel · O | ▼ Sale | 3,493 | $3.38 | $12K | -0.5% | — |
| Aug 11, 2026 | Stevens Christopher JamesChief Operating Officer · O | ▼ Sale | 36,658 | $3.5 | $128K | -6.8% | — |
| Aug 11, 2026 | Chaudhuri SarbaniSee Remarks · O | ▼ Sale | 4,701 | $3.5 | $16K | -1.8% | — |
| May 21, 2026 | Shah GauravCEO · O | ▼ Sale | 55,684 | $3.09 | $172K | -5% | — |
| May 7, 2026 | Chaudhuri SarbaniSee Remarks · O | ▼ Sale | 17,650 | $3.84 | $68K | -6.2% | — |
| Feb 18, 2026 | Militello JohnSee Remarks · O | ▼ Sale | 1,157 | $3.34 | $4K | -1.3% | — |
| Feb 18, 2026 | Shah GauravCEO · O | ▼ Sale | 5,990 | $3.34 | $20K | -0.6% | — |
| Feb 18, 2026 | Wilson MartinGeneral Counsel · O | ▼ Sale | 1,376 | $3.34 | $5K | -0.2% | — |
| Feb 13, 2026 | Wilson MartinGeneral Counsel · O | ▼ Sale | 12,253 | $3.31 | $41K | -1.8% | — |
| Feb 13, 2026 | Militello JohnSee Remarks · O | ▼ Sale | 3,726 | $3.31 | $12K | -3.9% | — |
| Feb 13, 2026 | Shah GauravCEO · O | ▼ Sale | 12,279 | $3.31 | $41K | -1.2% | — |
| Jan 2, 2026 | Bjork ElisabethD | ▲ Buy | 10,000 | $3.44 | $34K | +25% | — |
| Nov 18, 2025 | Militello JohnSee Remarks · O | ▼ Sale | 1,086 | $2.98 | $3K | -1.6% | — |
| Nov 18, 2025 | Schwartz Jonathan DavidSee Remarks · O | ▼ Sale | 2,545 | $2.98 | $8K | -0.8% | — |
| Nov 18, 2025 | Shah GauravCEO · O·D | ▼ Sale | 6,276 | $2.98 | $19K | -0.8% | — |
| Nov 18, 2025 | Wilson MartinGeneral Counsel · O | ▼ Sale | 1,646 | $2.98 | $5K | -0.4% | — |
| Oct 14, 2025 | Militello JohnSee Remarks · O | ▼ Sale | 28,918 | $3.96 | $115K | -30.1% | 4 tranches |
| Aug 27, 2025 | Bjork ElisabethD | ▲ Buy | 10,000 | $3.41 | $34K | +33.3% | — |
| Aug 19, 2025 | Militello JohnSee Remarks · O | ▼ Sale | 1,060 | $3.04 | $3K | -1.9% | 2 tranches |
| Aug 19, 2025 | Schwartz Jonathan DavidSee Remarks · O | ▼ Sale | 2,485 | $3.04 | $8K | -1.1% | 2 tranches |
| Aug 19, 2025 | Wilson MartinGeneral Counsel · O | ▼ Sale | 1,592 | $3.04 | $5K | -1.2% | 2 tranches |
| Aug 14, 2025 | Schwartz Jonathan DavidSee Remarks · O | ▼ Sale | 11,161 | $3.02 | $34K | -4.7% | — |
| Aug 14, 2025 | Militello JohnSee Remarks · O | ▼ Sale | 7,043 | $3.02 | $21K | -11% | — |
| Aug 14, 2025 | Wilson MartinGeneral Counsel · O | ▼ Sale | 12,109 | $3.02 | $37K | -8.1% | — |
Every $RCKT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Rocket Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RCKT feed.